生物医药公司昭衍新药(06127)11月4日早盘股价大涨逾20%,引发市场广泛关注。公司发布公告,作为生物医药领域代表性服务贸易企业,拟参与由财政部、商务部与招商局资本共同发起设立的服务贸易创新发展引导基金二期。公司或其指定子公司作为有限合伙人将认缴出资不超过1亿元人民币。
分析人士认为,昭衍新药参与服贸二期基金是从战略层面上夯实产业基础、布局医疗健康产业的积极尝试。借助专业投资机构的专业判断及投资管理优势,公司有望提升盈利能力,为后期打造新的利润增长点,实现公司的持续发展。
市场对此举持积极评价,相信昭衍新药将凭借新的发展动力进一步拓展产业布局、增强综合实力。公司股价在利好消息刺激下出现大涨,早盘最高一度攀升超过20%,截至发稿时报10.24港元,涨幅19.36%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.